Новини

UEMS EBDVD Examination is a test of excellence in Dermatology and Venereology. It is designed to assess the knowledge and clinical skills requisite to the delivery of a high standard of dermatovenereological care both in hospitals and in independent clinical practices.

DATE OF THE NEXT EBDVD EXAMINATION: 14th October 2022 REMOTE ONLINE EXAMINATION

APPLICATION WILL START on 1st February, 2022

DEADLINES

Deadline for APPLICATION: 1st of May 2022

Deadline for PAYMENT: 15th of May 2022

EBDVD EXAMINATION FEE

550 EUR for candidates from the European Union Member State or the signatory country of the European Economic Area Agreement and the Switzerland

750 EUR for candidates from other countries

REMOTE ONLINE EXAMINATION - for those candidates who are able to ensure a secure room for their examination (classroom, meeting room, training room) in the hospital they work, university, headquarters of a national professional association and a reliable authorised person who would invigilate the examination (see „Requirements for the examination room, equipment and invigilator” in the chapter “INSTRUCTIONS FOR CANDIDATES”, see on our website).

STRUCTURE OF EXAMINATION

The examination is composed of 200 multiple choice questions (MCQs) with clinical slide collection included. The language available is English. The examination is divided into five sessions, each session has 40 questions.

 

ALL DETAILED INFORMATION is available on our website

https://www.uems-ebdv.org/web/index.php/uems-board-examination

а

New research presented at the European Academy of Dermatology and Venerology (EADV) 30th Congress reveals COVID-19 vaccine hesitancy in psoriasis and psoriatic arthritis patients is being driven by concerns about vaccine safety and aggravation of their underlying condition.

In a second study, also reported at EADV Congress, researchers found no associations between biological therapies and the risk of respiratory tract infections (RTI) or serious infections (SI), including COVID-19.

The findings from both of these studies provide valuable insights for educating and supporting psoriasis patients with regards to the impact of biological treatments on infection, and on the need for COVID-19 vaccinations.

A new prototype device that can be used at home to treat basal cell carcinoma (a type of skin cancer) significantly reduces pain, while achieving efficacy comparable with a hospital stay. These findings come from a breakthrough pilot study, presented today at the 30th European Association of Dermatology and Venerology (EADV) Congress.

 

New research presented today at the European Academy of Dermatology and Venerology (EADV) 30th Congress reveals a link between genital warts and the human leukocyte antigen (HLA) system - the part of the immune system which helps regulate immune responses. This exciting breakthrough sets a new path for potential mRNA vaccinations against HPV and other sexually transmitted diseases.

The researchers in Denmark identified 12 protective and seven risk gene variants in the HLA system of 65,791 blood donors that influence risk of genital warts.

Individuals with risk alleles were found to be less successful at recognising the HPV virus and therefore more likely to present with genital warts

Researcher Dr Pernille Lindsø Andersen, PhD Fellow, Department of Clinical Immunology and Department of Dermatology at Zealand University Hospital, Denmark